Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

N/ANo Longer AvailableNCT05238311

Pfizer

Overview

Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma

In Expanded Access, treating physicians are the Sponsors Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.

Study Type

EXPANDED_ACCESS

Conditions

Multiple Myeloma

Interventions

ElranatamabDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Must have relapsed/refractory multiple myeloma (RRMM) and be refractory to at least one immunomodulatory drug, one proteasome inhibitor and one anti-CD38 antibody. Must have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care and not be eligible for participation in any ongoing clinical trial. Additional eligibility criteria may be required.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.